Formulation and in vivo evaluation of ondansetron orally disintegrating tablets using different superdisintegran

DOI: 10.1007/s12272-011-1115-y
Archives of Pharmacal Research, 2011, 34, 1945-56.

#	Paper	IF	Citations
34	Meloxicam taste-masked oral disintegrating tablet with dissolution enhanced by ion exchange resins and cyclodextrin. *AAPS PharmSciTech*, **2013**, 14, 1118-28	3.9	9
33	In vitro and in vivo correlation of disintegration and bitter taste masking using orally disintegrating tablet containing ion exchange resin-drug complex. *International Journal of Pharmaceutics*, **2013**, 455, 31-9	6.5	36
32	Oral transmucosal drug delivery for pediatric use. *Advanced Drug Delivery Reviews*, **2014**, 73, 50-62	18.5	78
31	Dissolution methodology for taste masked oral dosage forms. *Journal of Controlled Release*, **2014**, 173, 32-42	11.7	48
30	Formulation, evaluation and 3(2) full factorial design-based optimization of ondansetron hydrochloride incorporated taste masked microspheres. *Pharmaceutical Development and Technology*, **2014**, 19, 839-52	3.4	17
29	Formulation and evaluation of lipid based taste masked granules of ondansetron HCl. *European Journal of Pharmaceutical Sciences*, **2014**, 62, 180-8	5.1	16
28	Preparation and evaluation of orally disintegrating tablets containing vitamin E as a model fat-soluble drug. *Chemical and Pharmaceutical Bulletin*, **2015**, 63, 156-63	1.9	5
27	The Disintegration Process in Microcrystalline Cellulose Based Tablets, Part 1: Influence of Temperature, Porosity and Superdisintegrants. *Journal of Pharmaceutical Sciences*, **2015**, 104, 3440-50	3.9	59
26	Preparation and evaluation of orally disintegrating tablets of taste masked phencynonate HCl using ion-exchange resin. *Drug Development and Industrial Pharmacy*, **2015**, 41, 934-41	3.6	17
25	Formulation and evaluation of meloxicam oral disintegrating tablet with dissolution enhanced by combination of cyclodextrin and ion exchange resins. *Drug Development and Industrial Pharmacy*, **2015**, 41, 1006-16	3.6	18
24	Microstructural investigation using synchrotron radiation X-ray microtomography reveals taste-masking mechanism of acetaminophen microspheres. *International Journal of Pharmaceutics*, **2016**, 499, 47-57	6.5	16
23	Formulation and characterization of taste masked ondansetron-magnesium aluminum silicate adsorption systems. *Drug Development and Industrial Pharmacy*, **2016**, 42, 1291-9	3.6	8
22	9,10-Dihydrophenanthrene derivatives and one 1,4-anthraquinone firstly isolated from Dioscorea zingiberensis C. H. Wright and their biological activities. *Fitoterapia*, **2016**, 109, 20-4	3.2	12
21	A Review of Disintegration Mechanisms and Measurement Techniques. *Pharmaceutical Research*, **2017**, 34, 890-917	4.5	132
20	In vitro and in vivo investigation of taste-masking effectiveness of Eudragit E PO as drug particle coating agent in orally disintegrating tablets. *Drug Development and Industrial Pharmacy*, **2017**, 43, 723-731	3.6	21
19	Palatability and Preference of Gummi Formulations with Various Pharmaceutical Characteristics. *Chemical and Pharmaceutical Bulletin*, **2018**, 66, 452-457	1.9	3
18	Taste Masking Approaches for Medicines. *Current Drug Delivery*, **2018**, 15, 167-185	3.2	23

17	Structural and in vitro in vivo evaluation for taste masking. *Expert Opinion on Drug Delivery*, **2018**, 15, 1105-1116	8	2
16	Quinoa protein: Composition, structure and functional properties. *Food Chemistry*, **2019**, 299, 125161	8.5	82
15	Orally disintegrating tablets and orally disintegrating mini tablets - novel dosage forms for pediatric use. *Pharmaceutical Development and Technology*, **2019**, 24, 902-914	3.4	27
14	Novel sublingual tablets of Atorvastatin calcium/Trimetazidine hydrochloride combination; HPTLC quantification, formulation and characterization. *Saudi Pharmaceutical Journal*, **2019**, 27, 540-549	4.4	6
13	RSM-Based Design and Optimization of Transdermal Film of Ondansetron HCl. *Journal of Pharmaceutical Innovation*, **2020**, 15, 94-109	1.8	5
12	Design and optimization of film-forming gel of etoricoxib using research surface methodology. *Drug Delivery and Translational Research*, **2020**, 10, 498-514	6.2	5
11	Effect of excipients on oral absorption process according to the different gastrointestinal segments. *Expert Opinion on Drug Delivery*, **2021**, 18, 1005-1024	8	3
10	Selective Laser Sintering 3D Printing of Orally Disintegrating Printlets Containing Ondansetron. *Pharmaceutics*, **2020**, 12,	6.4	56
9	BIOAVAILABILITY STUDY OF ONDANSETRON GEL IN RABBITS AND HUMAN VOLUNTEERS APPLING UPLC AS ANALYTICAL TOOL AND EVALUATION OF THE ANTIEMETIC EFFECT OF ONDANSETRON GEL IN CISPLATIN-INDUCED EMESIS IN RATS. *International Journal of Pharmacy and Pharmaceutical Sciences*, **2020**, 68-82	0.3	
8	Formulation and evaluation of niosomal vesicles containing ondansetron HCL for trans-mucosal nasal drug delivery. *Drug Development and Industrial Pharmacy*, **2020**, 46, 751-761	3.6	9
7	Physicochemical, functional and structural characteristics of grains, flour and protein isolates of Indian quinoa lines. *Food Research International*, **2021**, 140, 109982	7	8
6	Characterization of orodispersible tablets and orodispersible films. *Arhiv Za Farmaciju*, **2018**, 68, 839-859	0.2	
5	Optimization and Quality by Design Approach for Piroxicam Fast Dissolving Tablet Formulations Using Box-Behnken Design. *Current Drug Therapy*, **2020**, 15, 152-165	0.7	0
4	Recent Strategic Developments in the Use of Superdisintegrants for Drug Delivery. *Current Pharmaceutical Design*, **2020**, 26, 701-709	3.3	1
3	Puzzle out Machine Learning Model-Explaining Disintegration Process in ODTs.. *Pharmaceutics*, **2022**, 14,	6.4	0
2	Personalised Esomeprazole and Ondansetron 3D Printing Formulations in Hospital Paediatric Environment: I-Pre-Formulation Studies. **2022**, 12, 10585		0
1	Effect of starch, cellulose and povidone based superdisintegrants in a QbD-based approach for the development and optimization of Nitazoxanide orodispersible tablets: Physicochemical characterization, compaction behavior and in-silico PBPK modeling of its active metabolite Tizoxanide. **2023**, 79, 104079		0